← Leaderboards
Miriam Gochin
University Of The Pacific-Stockton
$3,067,073
Attributed
$3,067,073
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $478.9K · FY2005–20$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,067,073 · 7
By mechanism
R21$1,965,192 · 6
R01$1,101,881 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Binding Sites”
- Barton F Haynes · Duke University$271,615,822
- Michael P Snyder · Yale University$102,650,300
- David Heimbrook · Leidos Biomedical Research, Inc.$93,692,184
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Myron S Cohen · Family Health International$91,263,426
- Paul S. Aisen · Cognition Therapeutics, Inc.$72,776,809
Research focus
Binding SitesStructureCellsInhibitor/AntagonistLigandsPreventDesignInfectionVirusViralPharmaceutical PreparationsPeptidesSmall MoleculeMolecular WeightBaseComplexScaffoldLinkHiv-1SiteAffinityT-20ReceptorCell Fusion
Grant awards (16)
Covalent capture of small molecule - gp41 complexes$178,750
R21 · FY2020 · AI · contact PI
Covalent capture of small molecule - gp41 complexes$214,500
R21 · FY2019 · AI · contact PI
Mechanism of indole compounds as HIV fusion inhibitors$178,750
R21 · FY2017 · AI · contact PI
Mechanism of indole compounds as HIV fusion inhibitors$214,500
R21 · FY2016 · AI · contact PI
Structure-based discovery and development of HIV-1 gp41 fusion inhibitors$265,215
R01 · FY2013 · GM · contact PI
Structure-based discovery and development of HIV-1 gp41 fusion inhibitors$274,527
R01 · FY2012 · GM · contact PI
Rational design of indole compounds as HIV fusion inhibitors$180,875
R21 · FY2012 · AI · contact PI
Structure-based discovery and development of HIV-1 gp41 fusion inhibitors$274,829
R01 · FY2011 · GM · contact PI
Rational design of indole compounds as HIV fusion inhibitors$204,042
R21 · FY2011 · AI · contact PI
Structure-based discovery and development of HIV-1 gp41 fusion inhibitors$287,310
R01 · FY2010 · GM · contact PI
Assay development for high affinity non-peptide HIV-1 gp41 inhibitors$144,700
R21 · FY2009 · NS · contact PI
High-Throughput Screening for Human Immunodeficiency Virus Fusion Inhibitors$38,250
R21 · FY2008 · NS · contact PI
High-Throughput Screening for Human Immunodeficiency Virus Fusion Inhibitors$207,125
R21 · FY2007 · NS · contact PI
METALLOPEPTIDES OF GP41 IN HIV-1 FUSION INHIBITION$108,356
R21 · FY2005 · AI
METALLOPEPTIDES OF GP41 IN HIV-1 FUSION INHIBITION$93,494
R21 · FY2005 · AI
METALLOPEPTIDES OF GP41 IN HIV-1 FUSION INHIBITION$201,850
R21 · FY2004 · AI